Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) – Piper Jaffray Companies issued their Q1 2020 EPS estimates for shares of Amphastar Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 12th. Piper Jaffray Companies analyst D. Amsellem anticipates that the company will post earnings per share of $0.16 for the quarter. Piper Jaffray Companies currently has a “Neutral” rating and a $23.00 target price on the stock. Piper Jaffray Companies also issued estimates for Amphastar Pharmaceuticals’ Q2 2020 earnings at $0.23 EPS, Q3 2020 earnings at $0.28 EPS and Q4 2020 earnings at $0.30 EPS.

AMPH has been the topic of a number of other research reports. Zacks Investment Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 9th. Needham & Company LLC downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 target price on the stock. in a research report on Wednesday. BidaskClub raised Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 3rd. Finally, TheStreet upgraded Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Friday, January 11th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Amphastar Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $23.73.

NASDAQ:AMPH opened at $20.50 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.34 and a current ratio of 2.02. The stock has a market capitalization of $1.11 billion, a P/E ratio of 97.62, a P/E/G ratio of 1.81 and a beta of 1.40. Amphastar Pharmaceuticals has a 52-week low of $14.40 and a 52-week high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.02. Amphastar Pharmaceuticals had a positive return on equity of 3.25% and a negative net margin of 1.96%. The firm had revenue of $89.69 million for the quarter, compared to the consensus estimate of $75.46 million.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Texas Permanent School Fund raised its position in Amphastar Pharmaceuticals by 3.6% during the fourth quarter. Texas Permanent School Fund now owns 22,624 shares of the company’s stock valued at $450,000 after purchasing an additional 796 shares in the last quarter. LS Investment Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 217.9% during the 4th quarter. LS Investment Advisors LLC now owns 3,522 shares of the company’s stock worth $70,000 after purchasing an additional 2,414 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Amphastar Pharmaceuticals by 3.6% during the 3rd quarter. Legal & General Group Plc now owns 74,224 shares of the company’s stock worth $1,425,000 after purchasing an additional 2,568 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Amphastar Pharmaceuticals by 5.8% during the 4th quarter. Arizona State Retirement System now owns 53,243 shares of the company’s stock worth $1,060,000 after purchasing an additional 2,918 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth about $63,000. Institutional investors own 48.22% of the company’s stock.

In other news, CFO William J. Peters sold 1,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $25.36, for a total value of $38,040.00. Following the completion of the sale, the chief financial officer now directly owns 77,050 shares in the company, valued at $1,953,988. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Yakob Liawatidewi sold 3,183 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, January 16th. The shares were sold at an average price of $22.15, for a total transaction of $70,503.45. Following the completion of the sale, the senior vice president now owns 37,471 shares of the company’s stock, valued at $829,982.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 87,222 shares of company stock valued at $2,037,797. Corporate insiders own 31.50% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Further Reading: What is the NASDAQ?

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.